GSK passes three significant milestones with new cancer drug given a double boostProactive Investors • 12/16/24
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?Zacks Investment Research • 12/11/24
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritisGlobeNewsWire • 12/10/24
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine MenveoZacks Investment Research • 11/28/24
GSK's receives European Commission green light for liquid form of key vaccineProactive Investors • 11/27/24
GSK submits multiple myeloma treatment for approval to the US regulatorProactive Investors • 11/25/24
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III StudyZacks Investment Research • 11/20/24
GSK trial shows promising results for treatment of persistent itch in rare liver diseaseProactive Investors • 11/19/24
GSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)Seeking Alpha • 11/15/24